DE602005011656D1 - Verfahren zur behandlung von dickdarmkrebs mit botulinum neurotoxin - Google Patents

Verfahren zur behandlung von dickdarmkrebs mit botulinum neurotoxin

Info

Publication number
DE602005011656D1
DE602005011656D1 DE602005011656T DE602005011656T DE602005011656D1 DE 602005011656 D1 DE602005011656 D1 DE 602005011656D1 DE 602005011656 T DE602005011656 T DE 602005011656T DE 602005011656 T DE602005011656 T DE 602005011656T DE 602005011656 D1 DE602005011656 D1 DE 602005011656D1
Authority
DE
Germany
Prior art keywords
cancer
thick
treatment
botulinum neurotoxin
neurotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005011656T
Other languages
English (en)
Inventor
Mitchell F Brin
Stephen Donovan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE602005011656D1 publication Critical patent/DE602005011656D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE602005011656T 2004-08-27 2005-07-21 Verfahren zur behandlung von dickdarmkrebs mit botulinum neurotoxin Active DE602005011656D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/929,040 US7838008B2 (en) 1999-12-07 2004-08-27 Methods for treating diverse cancers
PCT/US2005/026252 WO2006025976A1 (en) 2004-08-27 2005-07-21 Methods for treating cancer

Publications (1)

Publication Number Publication Date
DE602005011656D1 true DE602005011656D1 (de) 2009-01-22

Family

ID=35094495

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005011656T Active DE602005011656D1 (de) 2004-08-27 2005-07-21 Verfahren zur behandlung von dickdarmkrebs mit botulinum neurotoxin

Country Status (15)

Country Link
US (1) US7838008B2 (de)
EP (2) EP1990059A3 (de)
JP (1) JP4922167B2 (de)
KR (1) KR101234486B1 (de)
CN (1) CN101031317B (de)
AR (1) AR050713A1 (de)
AT (1) ATE416786T1 (de)
AU (1) AU2005280574A1 (de)
BR (1) BRPI0515352A (de)
CA (1) CA2580748A1 (de)
DE (1) DE602005011656D1 (de)
ES (1) ES2317284T3 (de)
MX (1) MX2007002127A (de)
TW (1) TWI364293B (de)
WO (1) WO2006025976A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
CN100525831C (zh) * 2002-12-20 2009-08-12 肉毒素研究同仁股份有限公司 改进的药用肉毒杆菌毒素组合物
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
AU2005279741B2 (en) 2004-09-01 2011-10-06 Allergan, Inc. Degradable clostridial toxins
US8343929B2 (en) * 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
ES2373963T3 (es) 2004-09-23 2012-02-10 Toxcure, Inc. Tratamiento de neoplasmas con neurotoxina.
FR2879462B1 (fr) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic Utilisation de toxine botulique pour une insensibilisation locale prolongee
AU2006227816B2 (en) 2005-03-15 2012-04-05 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
WO2007015174A2 (en) * 2005-07-08 2007-02-08 Exothera L.L.C. Exosome-specific ligands, their preparartion and uses
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
AU2007329579A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
US10466245B2 (en) 2008-02-20 2019-11-05 The Secretary Of State For Health Covalently linked thermostable kinase for decontamination process validation
GB0803068D0 (en) 2008-02-20 2008-03-26 Health Prot Agency Cross-linked biological indicator
US20110158973A1 (en) * 2008-06-12 2011-06-30 Syntaxin Limited Suppression of cancers
WO2009150470A2 (en) * 2008-06-12 2009-12-17 Syntaxin Limited Suppression of cancers
US8796216B2 (en) * 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
EP2310028B1 (de) * 2008-06-12 2016-11-16 Ipsen Bioinnovation Limited Fusionsproteine zur Verwendung bei der Behandlung von Akromegalie
BRPI0914630A2 (pt) * 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
CN101386648B (zh) * 2008-09-25 2012-05-30 中国人民解放军军事医学科学院微生物流行病研究所 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途
GB0820970D0 (en) * 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
WO2010062955A1 (en) 2008-11-26 2010-06-03 Toxcure, Inc. Treating neoplasms with neurotoxin
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US8663210B2 (en) * 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
KR20140015129A (ko) * 2009-08-14 2014-02-06 알러간, 인코포레이티드 성장 인자 재표적화된 엔도펩티다아제를 사용하여 암을 치료하는 방법
WO2011020056A2 (en) * 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using galanin retargeted endpeptidases
WO2011020052A1 (en) * 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using opioid retargeted endpeptidases
CN102574899A (zh) * 2009-08-14 2012-07-11 阿勒根公司 使用胰高血糖素样激素再靶向内肽酶治疗癌症的方法
WO2011020114A2 (en) * 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using tachykinin retargeted endopeptidases
CA2771297A1 (en) * 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using neurotrophin retargeted endopeptidases
WO2012112434A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using retargeted endopeptidases
US20120207742A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Treatments Using PSMA Ligand Endopeptidases
US20120244188A1 (en) * 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251574A1 (en) * 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251575A1 (en) * 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
CA2835885C (en) * 2011-05-17 2020-08-25 Niiki Pharma Aquisition Corp. 2 Medicaments and methods for treating cancer
CN103813802A (zh) 2011-07-14 2014-05-21 阿勒根公司 用于治疗与性活动相关的失禁的方法
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
WO2014059279A2 (en) * 2012-10-13 2014-04-17 The University Of Toledo Materials and methods useful to treat neuroblastomas and pheochromocytomas
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US10647750B2 (en) 2015-01-09 2020-05-12 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (de) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Herstellung von aktivierten clostridien-neurotoxinen
US20210277071A1 (en) 2016-09-29 2021-09-09 Ipsen Biopharm Limited Hybrid neurotoxins
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
JP7186228B2 (ja) 2018-02-26 2022-12-08 イプセン バイオファーム リミテッド 非細胞毒性プロテアーゼの注入を案内するための超音波の使用
CN116133686A (zh) * 2020-07-23 2023-05-16 玫帝托克斯股份有限公司 癌症治疗剂
WO2022019583A1 (ko) * 2020-07-23 2022-01-27 (주)메디톡스 엑소좀-매개된 질환 치료제
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31648A (en) * 1861-03-05 Improvement in silicated soaps
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US4725540A (en) * 1984-07-09 1988-02-16 Emil Underberg Process for the preparation of amine-oxidase containing material, so produced amine-oxidase containing material
US5183462A (en) 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5466672A (en) 1992-12-04 1995-11-14 Ophidian Pharmaceuticals, Inc. Therapeutic use of clostridium difficile toxin A
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
EP0737074B1 (de) 1993-12-28 2001-08-01 Allergan Sales, Inc. Botulinumtoxine zur behandlung von hyperhydrosis
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
DK0758900T3 (da) 1994-05-09 2002-07-29 William J Binder Botulinumtoksin til reduktion af migræne-hovedpinesmerter
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
PT1011695E (pt) 1997-07-15 2006-07-31 Univ Colorado Utilizacao de terapia com neurotoxina para tratamento de doencas da prostata
US7470431B2 (en) 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
DE19802569A1 (de) 1998-01-23 1999-09-09 Univ Albert Ludwigs Freiburg Toxikologisch aktive Fragmente des lethalen Toxins von Clostridium sordellii und deren Verwendung in Immuntoxinen
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
AU1706400A (en) 1998-10-27 2000-05-15 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
DE19852981A1 (de) 1998-11-17 2000-05-18 Martin Schmidt Botulinum-Toxine, deren Derivate, Analoge und molekulare Bruchstücke zur topischen epicutanen Anwendung auch in Zusammenwirken mit hautpenetrationsfördernden Substanzen und Maßnahmen in Zubereitungsformen zur Beeinflussung acetylcholinabhängiger Körperfunktionen
DE19856052A1 (de) 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6565870B1 (en) 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
WO2002009743A1 (en) 2000-08-02 2002-02-07 Allergan Sales, Inc. Method for treating a neoplasm
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6827931B1 (en) * 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
WO2003011333A1 (en) 2001-07-27 2003-02-13 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
US20030224019A1 (en) 2002-03-01 2003-12-04 O'brien Christopher Methods of treating nerve entrapment syndromes
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions

Also Published As

Publication number Publication date
CA2580748A1 (en) 2006-03-09
JP2008511627A (ja) 2008-04-17
TWI364293B (en) 2012-05-21
EP1990059A3 (de) 2009-09-30
AU2005280574A1 (en) 2006-03-09
TW200618808A (en) 2006-06-16
EP1990059A2 (de) 2008-11-12
MX2007002127A (es) 2007-03-30
US7838008B2 (en) 2010-11-23
KR20070045292A (ko) 2007-05-02
AR050713A1 (es) 2006-11-15
ES2317284T3 (es) 2009-04-16
WO2006025976A1 (en) 2006-03-09
EP1804827A1 (de) 2007-07-11
BRPI0515352A (pt) 2008-07-15
ATE416786T1 (de) 2008-12-15
JP4922167B2 (ja) 2012-04-25
US20050031648A1 (en) 2005-02-10
CN101031317A (zh) 2007-09-05
KR101234486B1 (ko) 2013-02-18
EP1804827B1 (de) 2008-12-10
CN101031317B (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
DE602005011656D1 (de) Verfahren zur behandlung von dickdarmkrebs mit botulinum neurotoxin
ATE489955T1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
DE602005008970D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten
DE602006019753D1 (de) Verfahren und gerät zur behandlung von aneurysmen der a. thoracica
DE602007006451D1 (de) Verfahren zur behandlung von bohrlöchern mit wiederverwertbaren flüssigkeiten
ATE474602T1 (de) Verfahren zur behandlung von hiv-infektion
DE602004021790D1 (de) Verfahren zur behandlung von parkinson-krankheit
DE602005016292D1 (de) Verfahren zur herstellung von glatiramer
DE602006018354D1 (de) Verfahren zur behandlung von abnormalem zellwachstum
DE602007006479D1 (de) Verfahren und vorrichtungen zur behandlung von mehreren bohrlochintervallen
ATE500824T1 (de) Verfahren zur reinigung von trans-(-)-delta9- tetrahydrocannabinol und trans-(+)-delta9- tetrahydrocannabinol
ATE463162T1 (de) Verfahren zur verstärkung der wirksamkeit von ethaboxam
DE602005019454D1 (de) Verfahren zur herstellung von aloe-emodin
DE112004001806D2 (de) Verfahren zur Selbstjustierenden Verkleinerung von Strukturen
DE602006020201D1 (de) Aerobes-anaerobes Verfahren zur Behandlung von organisch belasteten Abwässern
ATE406372T1 (de) Verfahren zur herstellung von 3-o-geschützten morphinonen und 3-o-geschützten morphinondienolcarboxylaten
ATE411803T1 (de) Verfahren zur behandlung von schwerer herzinsuffizienz und medikament dafür
ATE394369T1 (de) Verfahren zur aufreinigung von mesotrion
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
DE602005027251D1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
DE602004018249D1 (de) Verfahren zur Dearomatisierung von Molkeprotein
ATA6612003A (de) Verfahren zur reinigung von abwässern
DE602005017312D1 (de) Form und verfahren zur ausbildung von kunststoffprodukten
DE602004010548D1 (de) Verfahren zur behandlung von tierhäuten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition